Harbour Trust & Investment Management Co Purchases 1,139 Shares of Eli Lilly and Company $LLY

Key Points

• Harbour Trust & Investment Management increased its Eli Lilly position by 7.3%, purchasing 1,139 shares to hold 16,672 shares valued at approximately $19.3 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with EPS of $7.48 beating estimates of $5.71 and revenue rising 38.6% year over year to $24.4 billion. The stock traded up 3.1% at $1,415.64, near its 12-month high.
• Analysts remain broadly bullish, with an average “Moderate Buy” rating and a $1,398.43 price target, while investors should note valuation and execution risks, including pricing pressure and the company’s heavy reliance on GLP-1 drugs.

Harbour Trust & Investment Management Co increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.3% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,672 shares of the company's stock after buying an additional 1,139 shares during the period. Eli Lilly and Company accounts for approximately 1.9% of Harbour Trust & Investment Management Co's portfolio, making the stock its 16th largest holding. Harbour Trust & Investment Management Co's holdings in Eli Lilly and Company were worth $19,291,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Integrity Financial Corp WA increased its stake in Eli Lilly and Company by 1.3% in the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock worth $767,000 after acquiring an additional 8 shares during the last quarter. LCM Capital Management Inc raised its stake in Eli Lilly and Company by 3.3% in the third quarter. LCM Capital Management Inc now owns 253 shares of the company's stock valued at $293,000 after purchasing an additional 8 shares in the last quarter. Smith Shellnut Wilson LLC ADV raised its position in shares of Eli Lilly and Company by 4.1% during the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company's stock valued at $235,000 after buying an additional 8 shares in the last quarter. Financial Network Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 5.6% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company's stock worth $175,000 after acquiring an additional 8 shares during the last quarter. Finally, Willner & Heller LLC grew its position in Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company's stock worth $1,100,000 after acquiring an additional 9 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday. Royal Bank Of Canada increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an "outperform" rating in a research report on Friday. Sanford C. Bernstein reissued an "outperform" rating and set a $1,450.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 26th. Bank of America reaffirmed a "buy" rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a research note on Friday. Finally, Berenberg Bank raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 price target for the company in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $1,398.43.

Eli Lilly and Company Trading Up 3.1%

NYSE:LLY opened at $1,415.64 on Friday. The company has a 50-day moving average price of $1,197.72 and a 200-day moving average price of $1,092.57. Eli Lilly and Company has a 12 month low of $834.19 and a 12 month high of $1,449.68. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.95, a P/E/G ratio of 1.78 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 93.68%. The company had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. During the same quarter in the previous year, the company earned $7.02 earnings per share. Eli Lilly and Company's quarterly revenue was up 38.6% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio is currently 22.46%.

Insider Transactions at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company's stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.